Concepedia

Author

Andrea Gallamini

Azienda Sanitaria Ospedaliera S.Croce e Carle CuneoORCID

Also Known As

A Gallamini, A. GALLAMINI, A. Gallamini, Andrea Gallamini, Andrea Gallamini, MD, Andrea Gallamini, MD (Editor), Andrea Gallamini, MD (Editor),, Gallamini A, Gallamini Andrea, Gallamini, A.

393

Publications

15.9K

Citations

64

H-Index

81

Concepts

All Affiliations

Azienda Sanitaria Ospedaliera S.Croce e Carle CuneoCentre Antoine LacassagneIstituti di Ricovero e Cura a Carattere ScientificoUniversity of TurinAzienda Ospedaliero Universitaria San Giovanni Battista
AG

About

Andrea Gallamini is an author at Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo specializing in medicine, oncology, and pathology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

30

45

3.6K

2

Health Sciences

23

29

2.6K

3

Cell Biology

2

2

91

4

Cellular Therapies

2

2

135

5

Blood Transplantation

1

1

11

Andrea Gallamini

×

118

Publications

13.8K

Citations

60

H-Index

YearCitations

Early Interim 2-[ <sup>18</sup> F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study

Andrea Gallamini, Martin Hutchings, Luigi Rigacci,

Journal of Clinical Oncology

2007

829

Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin’s Lymphoma

Joseph M. Connors, Wojciech Jurczak, David J. Straus,

New England Journal of Medicine

2017

738

Report on the First International Workshop on interim-PET scan in lymphoma

Michel Meignan, Andrea Gallamini, Michel Meignan,

Leukemia & lymphoma/Leukemia and lymphoma

2009

731

Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study

Andrea Gallamini

Blood

2003

600

A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma

Benedetto Bruno, Marcello Rotta, Francesca Patriarca,

New England Journal of Medicine

2007

504

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)

Renato Bassan, Orietta Spinelli, Elena Oldani,

Blood

2009

429

ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned

Simonetta Viviani, Pier Luigi Zinzani, Alessandro Rambaldi,

New England Journal of Medicine

2011

419

Marker Expression in Peripheral T-Cell Lymphoma: A Proposed Clinical-Pathologic Prognostic Score

Philip Went, Claudio Agostinelli, Andrea Gallamini,

Journal of Clinical Oncology

2006

384

Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma

Sally F. Barrington, Wendi Qian, Edward J. Somer,

European Journal of Nuclear Medicine and Molecular Imaging

2010

338

Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial

Andrea Gallamini, Francesco Zaja, Caterina Patti,

Blood

2007

307

Page 1